Chronic viral hepatitis types B and C may eventually lead to the development of hepatocellular carcinoma. Although hepatitis B is readily preventable by vaccination, there is growing evidence that antiviral therapy directed against hepatitis B may reduce the risk of liver cancer among those already infected. There is no vaccine against hepatitis C, but the evidence is now strong that antiviral therapy with sustained virological response (viral cure) reduces, but does not eliminate, the risk of hepatocellular carcinoma
Background: The extent of the effect of antiviral therapy and its predictors in preventing hepatocel...
Chronic hepatitis B (CHB) accounts for approximately 50% of the underlying etiologies for the develo...
Hepatocellular carcinoma (HCC) is a frequent, long term complication of chronic infection with hepat...
Patients with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection are at significan...
Chronic hepatitis B (CHB) infection is the major cause of hepatocellular carcinoma (HCC), accounting...
Chronic hepatitis B is the main risk factor for hepatocellular carcinoma (HCC) in Asia. The most imp...
Hepatitis B virus (HBV) is a major health problem worldwide, with approximatively 240 million people...
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with the ma...
Prevention is the only realistic approach for reducing mortality rates associated with hepatocellula...
Since the discovery of the hepatitis B virus (HBV) by Blumberg et al. in 1965, its genome, sequence,...
Since the discovery of the hepatitis B virus (HBV) by Blumberg et al. in 1965, its genome, sequence,...
Hepatocellular carcinoma (HCC) is the fourth leading global cause of tumor-related mortality. HCC ha...
Chronic infections with either hepatitis B or C virus (HBV or HCV) are among the most common risk fa...
Hepatocellular carcinoma (HCC), especially hepatitis B virus (HBV)-related, remains a major cause of...
Hepatocellular carcinoma (HCC) is one of the most common causes of death from cancer and is the fina...
Background: The extent of the effect of antiviral therapy and its predictors in preventing hepatocel...
Chronic hepatitis B (CHB) accounts for approximately 50% of the underlying etiologies for the develo...
Hepatocellular carcinoma (HCC) is a frequent, long term complication of chronic infection with hepat...
Patients with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection are at significan...
Chronic hepatitis B (CHB) infection is the major cause of hepatocellular carcinoma (HCC), accounting...
Chronic hepatitis B is the main risk factor for hepatocellular carcinoma (HCC) in Asia. The most imp...
Hepatitis B virus (HBV) is a major health problem worldwide, with approximatively 240 million people...
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with the ma...
Prevention is the only realistic approach for reducing mortality rates associated with hepatocellula...
Since the discovery of the hepatitis B virus (HBV) by Blumberg et al. in 1965, its genome, sequence,...
Since the discovery of the hepatitis B virus (HBV) by Blumberg et al. in 1965, its genome, sequence,...
Hepatocellular carcinoma (HCC) is the fourth leading global cause of tumor-related mortality. HCC ha...
Chronic infections with either hepatitis B or C virus (HBV or HCV) are among the most common risk fa...
Hepatocellular carcinoma (HCC), especially hepatitis B virus (HBV)-related, remains a major cause of...
Hepatocellular carcinoma (HCC) is one of the most common causes of death from cancer and is the fina...
Background: The extent of the effect of antiviral therapy and its predictors in preventing hepatocel...
Chronic hepatitis B (CHB) accounts for approximately 50% of the underlying etiologies for the develo...
Hepatocellular carcinoma (HCC) is a frequent, long term complication of chronic infection with hepat...